DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells. "The data presented at ACC.25 continue to underscore the therapeutic value of icosapent ethyl (IPE) and EPA in potentially addressing known pathways of cardiovascular (CV) risk beyond LDL lowering for patients," said R. Preston Mason, Ph.D., Brigham and Women's Hospital. "While emerging t

Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ:AMRN) ("Amarin" or the "Company"), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the "Board") 88 Harcourt Street Dublin 2, Ireland Members of the Board, We are meaningful shareholders of Amarin. While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Boa

DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL. "At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl product, to reduce cardiovascular (CV) events in at-risk patients," said Steve Ketchum, EVP, President of R&D and Chief Scientific Officer at Amarin. "With the advancement of additio

JP Morgan resumed coverage of Amarin with a rating of Underweight

Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

SCHEDULE 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders

-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise -- -- Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the fourth quarter of 2024 and

DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's fourth quarter 2024 financial results in the pre-market hours on March 12th.   Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States:

 -- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches ---- Positive European Momentum Continues with Progress from Pricing & Reimbursement Efforts and Incremental Revenue Growth Driven Primarily by Spain and the UK ---- Company to Host Virtual Analyst & Investor Day November 14 ---- Company Remains Committed to Maintaining Public Listing – DUBLIN and BRIDGEWATER, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the third quarter ended

SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)